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The Hippo pathway controls organ size and tissue homeostasis by
regulating cell proliferation and apoptosis. The LATS-mediated
negative feedback loop prevents excessive activation of the effec-
tors YAP/TAZ, maintaining homeostasis of the Hippo pathway.
YAP and TAZ are hyperactivated in various cancer cells which lead
to tumor growth. Aberrantly increased O-GlcNAcylation has re-
cently emerged as a cause of hyperactivation of YAP in cancer cells.
However, the mechanism, which induces hyperactivation of TAZ
and blocks LATS-mediated negative feedback, remains to be eluci-
dated in cancer cells. This study found that in breast cancer cells,
abnormally increased O-GlcNAcylation hyperactivates YAP/TAZ and
inhibits LATS2, a direct negative regulator of YAP/TAZ. LATS2 is one
of the newly identified O-GlcNAcylated components in the MST-
LATS kinase cascade. Here, we found that O-GlcNAcylation at LATS2
Thr436 interrupted its interaction with the MOB1 adaptor protein,
which connects MST to LATS2, leading to activation of YAP/TAZ by
suppressing LATS2 kinase activity. LATS2 is a core component in the
LATS-mediated negative feedback loop. Thus, this study suggests
that LATS2 O-GlcNAcylation is deeply involved in tumor growth by
playing a critical role in dysregulation of the Hippo pathway in
cancer cells.
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The balance between cellular proliferation and apoptosis iscrucial for the development and maintenance of tissue ho-
meostasis in multicellular organisms. Cancer can result when this
balance is disrupted. The Hippo pathway is a signal transduction
pathway that controls cell proliferation, cell self-renewal, and
apoptosis (1, 2). The Hippo pathway is mediated by phosphory-
lation, as the pivotal elements of the mammalian Hippo pathway
consist of serine/threonine kinases, such as mammalian Ste20 like
kinase1/2 (MST1/2) and large tumor suppressor 1/2 (LATS1/2), in
addition to the effectors Yes-associated protein (YAP)/transcrip-
tional coactivator with PDZ-binding motif (TAZ) (3–6). Cell–cell
adhesion, cell–matrix adhesion, and contractile tension are phys-
ical cues for turning on the Hippo pathway (7, 8). In addition,
various hormonal cues, growth factors, and stressors, such as
hypoxia and energy depletion, also regulate the Hippo pathway
(9). Some of those stimuli activate MST1/2 by inducing phos-
phorylation at MST1/2 Thr183/Thr180 (10–12). Mps one binder 1
(MOB1) binds activated MST1/2 and this interaction induces a
conformational change in MOB1 to enable it to bind to LATS1/2
(13, 14). LATS1/2 are recruited to MST-MOB1 in the membrane
by neurofibromatosis 2 (NF2) (15). After formation of the MST-
MOB1-LATS complex, MST1/2 phosphorylate MOB1 and the
LATS1/2 hydrophobic motif (Thr1079 for LAST1 and Thr1041
for LATS2) (14). The phosphorylated MOB1-LATS1/2 complex is
detached from MST1/2 and then LATS1/2 are fully activated after
autophosphorylation of its activation loop (Ser909 for LAST1 and
Ser872 for LATS2) (14, 16). As a result, activated LATS1/2
phosphorylates serine on the YAP/TAZ HXRXXS motifs (5, 7,
17–19). Phosphorylation at YAP Ser127 and TAZ Ser89 causes
their cytoplasmic sequestration by inducing an interaction with 14-
3-3 (5, 7, 17). In addition, phosphorylation at YAP Ser381 and
TAZ Ser311 leads to their proteasomal degradation (18, 19).
Consequently, YAP/TAZ cannot act as a transcriptional coac-
tivator (5), so the transcription levels of essential genes for cell
proliferation and antiapoptosis decrease. The Hippo pathway is
dysregulated in cancer cells, which contributes to tumor growth,
development, and metastasis (6). It has been assumed that the
Hippo pathway might be suppressed by a nonmutational mecha-
nism because mutations in the core components of the Hippo
pathway are rare in cancer patients (6, 20–23).
Many studies have found that O-GlcNAcylation and O-GlcNAc
transferase (OGT) levels are abnormally high in cancer cells (24,
25). O-GlcNAcylation is a posttranslational modification that is
mediated by OGT (26–28), and O-GlcNAc is removed from
proteins by O-GlcNAcase (OGA) (29). O-GlcNAcylation affects
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various cellular processes, such as cell growth, mobility, metabo-
lism, and development, by regulating protein stability, localization,
activity, and protein–protein interactions (30–36). In particular, it is
well known that O-GlcNAcylation regulates phosphorylation-
mediated signaling pathways through interplay with phosphorylation
(37, 38). Therefore, it was hypothesized that the phosphorylation-
mediated Hippo pathway might be masked by an abnormal in-
crease of O-GlcNAcylation in cancer cells.
It was reported thatO-GlcNAcylation enhances YAP activity (32,
39, 40). This finding establishes a correlation between abnormally
high levels of O-GlcNAcylation and dysregulation of the Hippo
pathway in cancer cells. Activated YAP induces transcription of
NF2 and LATS2, which are involved in inactivating YAP/TAZ (41,
42). However, the mechanism that blocks this intrinsic negative
feedback in the Hippo pathway remains to be elucidated in cancer
cells. This study discloses the molecular inhibitory mechanism of the
Hippo pathway by LATS2 O-GlcNAcylation. This finding suggests
the possibility that LATS2 O-GlcNAcylation blocks the negative
feedback loop in the Hippo pathway and contributes to the exces-
sive proliferative potential of cancer cells by sustaining hyper-
activation of YAP/TAZ.
Results
MST1 and LATS2 Are Modified with O-GlcNAc. The breast cancer
cells MCF7, MDA-MB-468, and MDA-MB-231 expressed higher
levels of YAP/TAZ and had higher cellular O-GlcNAcylation
levels than those in normal MCF10A cells (SI Appendix, Fig.
S1). YAP/TAZ activity is also known to increase in these breast
cancer cells (43). This is a common feature in various cancer cells
(20, 44–46). YAP O-GlcNAcylation enhances its activity, and ac-
tivated YAP increases the cellular O-GlcNAcylation level by
promoting OGT transcription, creating a self-perpetuating cycle
(32, 39). However, the correlation between O-GlcNAcylation and
TAZ has been unknown. Activated YAP/TAZ induce transcrip-
tion of their negative regulators, NF2 and LATS2 (41, 42).
Therefore, YAP and TAZ reciprocally inhibit each other’s acti-
vation through this intrinsic negative feedback loop (41). Hyper-
activated YAP by O-GlcNAcylation may repress TAZ activation,
so it would be unexpected that TAZ would be hyperactivated in
cancer cells with abnormally high levels of O-GlcNAcylation.
Therefore, it was hypothesized that abnormally increased cellular
O-GlcNAcylation might cause hyperactivation of TAZ in cancer
cells. This hypothesis was tested using MDA-MB-231 cells which have
abnormally high levels of cellularO-GlcNAcylation and in which YAP/
TAZ are hyperactivated. RNA interference was employed to decrease
the expression of OGT, which effectively decreased the cellular
O-GlcNAcylation level (Fig. 1A). The decrease in O-GlcNAcylation
induced cytoplasmic sequestration of TAZ as well as YAP (Fig. 1 B
and C). The phosphorylation at YAP Ser127 and TAZ Ser89 by
LATS1/2 leads to cytoplasmic sequestration of YAP/TAZ (5, 7, 17).
Therefore, phosphorylation levels at the specific sites of both proteins
were observed under an OGT knockdown condition. OGT knock-
down increased phosphorylation at YAP Ser127 by 2.88-fold (Fig. 1D)
and TAZ Ser89 by 1.53-fold (Fig. 1E). These results indicate that
abnormally increased O-GlcNAcylation in MDA-MB-231 cells in-
duced activation of both effectors, YAP and TAZ.
O-GlcNAcylation of TAZ was not detected (32), so this study
was conducted to identify O-GlcNAc-modified proteins in the
MST-LATS kinase cascade upstream of YAP/TAZ. For this,
MST1/2 and LATS1/2 were independently transfected into
HEK293 cells, and immunoprecipitated MST1/2 and LATS1/2
were probed with anti-O-GlcNAc antibody. Immunoprecipitated
MST1 and LATS2 were O-GlcNAcylated, and O-GlcNAcylation
of these proteins increased in response to treatment with the
OGA inhibitor Thiamet-G (Fig. 1 F and I). However, O-GlcNAc
was not detected on MST2 and LATS1 (Fig. 1 G and H). In
addition, it was confirmed that O-GlcNAcylation on MST1 and
LATS2 increased under an OGT overexpressing condition by the
terminal GlcNAc-specific lectin (sWGA) precipitation and im-
munoprecipitation (Fig. 1 J and K).
Glucose is the main source for O-GlcNAcylation, and extra-
cellular glucose status controls activation of the Hippo pathway
(47). Therefore, we confirmed whether the O-GlcNAcylation
levels of endogenous MST1 and LATS2 in MDA-MD-231 cells
change depending on extracellular glucose status. As a result, the
amount of sWGA-precipitated LATS2 dramatically increased
under the 25-mM glucose condition compared to the 5-mM
glucose condition (Fig. 1L). These results indicate that MST1
and LATS2 are O-GlcNAc modified components of the Hippo
pathway and that LATS2 O-GlcNAcylation is strongly affected
by extracellular glucose status.
LATS2 Is a Key Regulator Controlling the Hippo Pathway Depending
on the Cellular O-GlcNAcylation Level. LATS1/2 phosphorylates
YAP and TAZ at Ser127 and Ser89, respectively, and therefore
acts as a direct regulator of YAP/TAZ (5, 7, 17). Thus, it was
checked whether the phosphorylation level of the endogenous
LATS1/2 hydrophobic motif, which is necessary for LATS1/2
activation, changed depending on the cellular O-GlcNAcylation
level. OGT knockdown increased the amount of protein probed
with the anti-p-hydrophobic motif-LATS antibody (Fig. 2A). The
phosphorylation level of the LATS1 hydrophobic motif is not af-
fected by OGT knockdown (32, 39), so it was inferred that
phosphorylation of the LATS2 hydrophobic motif would increase
under an OGT knockdown condition. To confirm this inference,
exogenous LATS2 was immunoprecipitated and probed with
anti-p-hydrophobic motif-LATS antibody. Phosphorylation at the
hydrophobic motif of exogenous LATS2 was increased by OGT
knockdown (Fig. 2B).
MST1, another newly discoveredO-GlcNAcylated component, is a
serine/threonine kinase that phosphorylates the LATS2 hydrophobic
motif (14). If MST1 activity is regulated by its O-GlcNAcylation
status, an increase in phosphorylation of the LATS2 hydrophobic
motif could be induced by activated MST1 under the OGT knock-
down condition. However, phosphorylation levels at MST1 Thr183,
which are essential for MST1 activation, were unchanged despite a
significant global O-GlcNAcylation decrease caused by OGT knock-
down (Fig. 2C). These results indicate that the differences in LATS2
phosphorylation caused by changes in intracellular O-GlcNAcylation
occurred regardless of MST1 O-GlcNAcylation.
Thus, it was hypothesized that LATS2 O-GlcNAcylation might
inhibit phosphorylation of its hydrophobic motif. If this hy-
pothesis is correct, it is also possible that OGT knockdown en-
hances phosphorylation at YAP Ser127 by activating LATS2.
Thus, this study examined phosphorylation at YAP Ser127 in
LATS2/OGT double-knockdown (dKO) cells. The increase in
YAP phosphorylation levels caused by OGT knockdown was
lower in LATS2 knockdown cells than in LATS2 nonknockdown
cells (Fig. 2D). In addition, the reduction in phosphorylation at
YAP Ser127 in response to OGT overexpression was enhanced
by LATS2 overexpression (Fig. 2E). This result indicates that
LATS2 is deeply involved in the OGT-induced phosphorylation
of YAP. Taken together, there is a high probability that the
O-GlcNAcylation of LATS2 inhibits LATS2 activity by decreasing
the phosphorylation of its hydrophobic motif. Given that LATS2 is
not only a direct negative regulator of YAP/TAZ but also a crucial
component of the negative feedback loop in the Hippo pathway
(41, 42), it is possible that LATS2 O-GlcNAcylation has a signif-
icant effect on dysregulation of the Hippo pathway in cancer cells.
Therefore, this study focused on the O-GlcNAc modification
of LATS2.
Thr168, Ser340, and Thr436 Are the Major LATS2 O-GlcNAcylation
Sites. Myc-LATS2 and pCMV-OGT were transiently overex-
pressed in HEK293 cells to identify the LATS2 O-GlcNAcylation
sites. Immunoprecipitated Myc-LATS2 was subjected to sodium














































































OGT K/D - +















OGT K/D - +















































































































































































































Fig. 1. MST1 and LATS2, negative regulators of YAP/TAZ, are O-GlcNAcylated. (A–E) MDA-MB-231 cells were transfected with OGT siRNA or control (CTL)
siRNA for 48 h. (A) The cell lysates were immunoblotted with the relevant antibodies. (B and C) Localization of endogenous YAP (B) and TAZ (C) was detected
by immunofluorescence. (Scale bar, 50 μm.) Nuclear and cytoplasmic fractions were analyzed by immunoblotting with relevant antibodies. Lamin A/C and
α-tubulin were used as nuclear and cytoplasmic markers, respectively. (D and E) The phosphorylation levels at YAP Ser127 (D) and at TAZ Ser89 (E) were
determined by Western blotting. Each phosphorylation level was normalized to the total YAP or TAZ level. Data are presented as mean ± SEM from at least
three independent experiments. Statistical significance was determined by the two-tailed Student’s t test (*P < 0.05). (F–I) HEK293 cells were transfected with
Flag-MST1 (F), Flag-MST2 (G), HA-LATS1 (H), and HA-LATS2 (I) independently and then treated with 10 μM Thiamet-G for 24 h. The immunoprecipitated
exogenous proteins were immunoblotted with anti-O-GlcNAc antibody. (J and K) HEK293 cells were cotransfected Flag-MST1 (J) or HA-LATS2 (K) with OGT.
Immunoprecipitated Flag-MST1 and HA-LATS2 were immunoblotted with anti-O-GlcNAc antibody, and the sWGA precipitates were immunoblotted with
indicated antibodies. (L) MDA-MB-231 cells were incubated in media containing 5 or 25 mM glucose for 3 d. The sWGA precipitates were immunoblotted with
the relevant antibodies. Abbreviations: O/E (overexpression), K/D (knockdown), C (cytosol), N (nucleus).








dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and in-gel digestion with trypsin and then analyzed by Orbitrap
Fusion mass spectrometry in high collision dissociation (HCD) and
electron-transfer/higher-energy collision dissociation (Ethcd) fragmen-
tation modes. The identified putative LATS2 O-GlcNAcylation sites
are summarized in Fig. 3A. Seven putative LATS2 O-GlcNAcylation
sites were identified (Fig. 3 B–D and SI Appendix, Fig. S2). Four of
these sites (Thr168, Ser340, Ser342, and Ser346) existed on the linker
region and the remainder (Thr431, Thr433, and Thr436) occurred on
LCD2. To verify that the linker region and LCD2 were actually
O-GlcNAcylated, LATS2 deletion mutants (Δ161-402, deletion of the
linker region between LCD1 and LCD2; Δ403-480, deletion of LCD2
and a PAPA repeat) were transfected with pCMV-OGT. Both de-
letion mutants exhibited a significant decrease in O-GlcNAcylation
levels (Fig. 3E), indicating that O-GlcNAc is modified in the linker
region and LCD2.
To identify the major O-GlcNAcylation sites in LATS2, site-
specific O-GlcNAcylation-deficient mutants were generated by
substituting alanine for serine/threonine at each of the identified
sites. These mutants and pCMV-OGT were overexpressed in
HEK293 cells. A decrease in O-GlcNAcylation levels was ob-
served in the T168A, S340A, and T436A mutants (Fig. 3 F and
G). These results indicate that Thr168 and Ser340 are major
O-GlcNAcylation sites in the linker region and that Thr436 is the
major O-GlcNAcylation site in LCD2.
O-GlcNAcylation of LATS2 Prevents Its Own Phosphorylation by Disturbing
the Interaction withMOB1.To verify whether LATS2O-GlcNAcylation
inhibits phosphorylation at Thr1041 of the LATS2 hydrophobic
motif, wild-type LATS2 and each site-specific O-GlcNAcylation-de-
ficient mutant (T168A, S340A, and T436A) were stably expressed in
MDA-MB-231. Phosphorylation levels at the hydrophobic motif of
the T168A mutant and the T436A mutant were more than twice as
high as that of the wild type. The increase in phosphorylation level at
the hydrophobic motif of S340A mutant was less than that of T168A
and T436A and was not statistically significant (Fig. 4A). To clarify
the effect of O-GlcNAcylation at each site, OGT was knocked down
in each of the wild-type LATS2 and mutant LATS2-expressing cells
and phosphorylation of the LATS2 hydrophobic motif was checked.



















































































































































































Fig. 2. Phosphorylation of LATS2 hydrophobic motif changes depending on cellular O-GlcNAcylation status, but phosphorylation at MST1 Thr183 does not.
(A) MDA-MB-231 cells were transfected with OGT siRNA or CTL siRNA for 48 h, and the cell lysates were immunoblotted with the relevant antibodies. The
amount of phosphorylation of the LATS hydrophobic motif was normalized to that of LATS2. Data are presented as mean ± SEM from four independent
experiments. Statistical significance was determined by the two-tailed Student’s t test (*P < 0.05). (B) Endogenous OGT in Flag-LATS2 expressing MDA-MB-231
cells was knocked down by siRNA. Immunoprecipitated Flag-LATS2 was immunoblotted with anti-p-hydrophobic motif-LATS antibody. (C ) MDA-MB-231
cells were transfected with Flag-MST1 and OGT siRNA for 48 h. Immunoprecipitated Flag-MST1 was immunoblotted with anti-p-T183-MST1 antibody. (D)
MDA-MB-231 cells were transfected with OGT siRNA and LATS2 siRNA for 48 h. (E ) MDA-MB-231 cells were transfected with HA-LATS2 and OGT for 48 h.
(D and E ) Phosphorylation at YAP Ser127 was detected with anti-p-S127-YAP antibody. The amount of phosphorylation at YAP Ser127 was normalized to
that of YAP. Data are presented as mean ± SEM from three independent experiments. Abbreviations: O/E (overexpression), K/D (knockdown), HM
(hydrophobic motif).
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Domain Site
161-402 T168, S340, S342, S346
LCD2 (403-463) T431, T433, T436
m/z




















































































































































































































































































Fig. 3. LATS2 O-GlcNAcylation sites were identified. (A) A schematic drawing of the LATS2 O-GlcNAcylation regions based on mass spectrometry data
(Fig. 3 B–D and SI Appendix, Fig. S2). Abbreviations: LCD1 (LATS conserved domain 1), LCD2 (LATS conserved domain 2), PDB (protein binding domain), UBA
(ubiquitin-associated domain), AL (activation loop), HM (hydrophobic motif), PAPA (sequence with repeats of proline-alanine residues), PPxY (proline-proline-
any amino acid-tyrosine). Red letters indicate major LATS2 O-GlcNAcylation sites. (B–D) O-GlcNAcylation was detected at Thr168 (B), Ser340 (C), and Thr436
(D). (B) This peptide corresponds to residues 161 to 169, GLMPTPVTR. The O-GlcNAc oxonium ion (m/z, 204.09) and a series of its fragments (m/z, 186.08,
168.07, 138.05, and 126.05) were also assigned. (C) This peptide corresponds to residues 335 to 352, SQVFASDSPPQSLLTPSR. The O-GlcNAc oxonium ion (m/z,
204.09) and a series of its fragments (m/z, 186.08, 168.07, 138.06, 126.05) were also assigned. (D) This peptide corresponds to residues 422 to 445, AEPSL-
PAPNTVTAVTAAHILHPVK. The O-GlcNAc oxonium ion (m/z, 204.09) was also assigned. (B–D) O-GlcNAcylation detected residues are bolded and underlined.
(E–G) HEK293 cells were cotransfected with each indicated Myc-LATS2 and OGT. (E) Each immunoprecipitated LATS2 wild-type and deletion mutants was
immunoblotted with anti-O-GlcNAc antibody. Abbreviations: Δ161-402 (deletion of the linker region between LCD1 and LCD2), Δ403-480 (deletion of LCD2
and a PAPA repeat). (F and G) Each overexpressed Myc-LATS2 in HEK293 cells was immunoprecipitated with Myc antibody-conjugated A/G agarose beads.
Western blotting was performed with anti-O-GlcNAc antibody.








motif of the LATS2 mutants did not significantly increase under the
OGT knockdown condition (Fig. 4B). LATS2 requires additional
phosphorylation at Ser872 located in the activation loop to be fully
activated (14, 16). Phosphorylation of the activation loop showed
similar results as phosphorylation of the hydrophobic motif (Fig. 4C).
These results indicate that LATS2 O-GlcNAcylation, particularly at
the Thr168 and Thr436 residues, inhibited its phosphorylation at
Ser872 and Thr1041, which has a decisive effect on LATS2 activation.
Next, this study focused on the interaction between LATS2
and MOB1 to identify the molecular mechanism underlying
how LATS2 O-GlcNAcylation prevents phosphorylation of its
hydrophobic motif. MOB1 helps form the MST-MOB1-LATS2
complex by connecting MST to LATS2 (13, 14). This complex
formation is an indispensable step to phosphorylate the LATS2
hydrophobic motif by MST. There are two kinds of human MOB1
proteins, MOB1A and MOB1B, and they share 95% amino acid
sequence identity (48). Therefore, the effect of O-GlcNAcylation of
LATS2 on the LATS2-MOB1B interaction was verified. LATS1/2-
dKO HEK293A cells were chosen to rule out the influence of en-
dogenous LATS1/2. They showed similar results as MDA-MB-231
in which O-GlcNAcylation of LATS2 inhibits its phosphorylation at
Ser872 and Thr1041 (SI Appendix, Fig. S3). Wild-type LATS2 or
mutants were cotransfected with HA-MOB1B into LATS1/2-dKO
cells and treated with Thiamet-G for 24 h. Immunoprecipitated HA-
MOB1B showed a stronger interaction with LATS2 mutants com-
pared to wild-type LATS2, especially the T436A mutant (Fig. 4D).
These results indicate that O-GlcNAcylation of LATS2, particularly
O-GlcNAcylation at the Thr436 residue, blocked the LATS2-MOB1
interaction. Before LATS2 interacts with MOB1, NF2 recruits
LATS2 to the MST-MOB1 complex in the cell membrane by di-
rectly interacting with LATS2 (15). Therefore, the effects of LATS2
O-GlcNAcylation on the NF2-LATS2 interaction were evaluated.
There was no significant difference in the degree of NF2-wild-type
LATS2 interaction and the NF2-LATS2 mutant interaction (Fig. 4 E
and F). These results suggest that LATS2 O-GlcNAcylation directly
interrupted the interaction with MOB1.
O-GlcNAcylation at LATS2 Thr436 Interrupts the Hippo Pathway by
Inhibiting Its Own Activity. O-GlcNAcylation at LATS2 Thr168














































































































































































Fig. 4. O-GlcNAcylation of LATS2 inhibits its phosphorylation by blocking its interaction with MOB1B. (A) Flag-tagged wild-type (WT) LATS2 or LATS2
mutants was stably expressed in MDA-MB-231 cells, and immunoprecipitated Flag-LATS2 was detected with anti-p-hydrophobic motif-LATS antibody.
Phosphorylation levels at Thr1041 in hydrophobic motif of Flag-LATS2 were normalized to the Flag-LATS2 level. (B) Endogenous OGT in the indicated Flag-
LATS2-expressing MDA-MB-231 cells was knocked down by siRNA. Immunoprecipitated Flag-LATS2 was immunoblotted with anti-p-hydrophobic motif-LATS
antibody. (C) Wild-type LATS2 or LATS2 mutants were stably expressed in MDA-MB-231 cells. Immunoprecipitated Flag-LATS2 was detected with
anti-p-activation loop-LATS antibody. Phosphorylation levels at Ser872 in the activation loop of Flag-LATS2 were normalized to the Flag-LATS2 level. (D) HA-
MOB1B was expressed with Myc-tagged wild-type LATS2 or LATS2 mutants in LATS1/2-dKO HEK293A cells, and 10 μM Thiamet-G was added for 24 h. HA-
MOB1B was pulled down and Myc-LATS2 was detected by immunoblotting. (E and F) Indicated Myc-LATS2 and Flag-NF2 were cotransfected into LATS1/2-dKO
HEK293A and 10 μM Thiamet-G was added for 24 h. Cell lysates were subjected to immunoprecipitation using anti-Myc antibody, followed by immuno-
blotting for Flag-NF2 (E), or vice versa (F). (A and C) Data are presented as mean ± SEM from four independent experiments. Statistical significance was
determined by one-way ANOVA (*P < 0.05, **P < 0.01). Abbreviations: HM (hydrophobic motif), AL (activation loop).
14264 | www.pnas.org/cgi/doi/10.1073/pnas.1913469117 Kim et al.
crucial for its activation (Fig. 4 A and C). To confirm that
O-GlcNAcylation of LATS2 at these sites reduced its activity,
downstream targets of LATS2 were investigated in LATS1/2-
dKO HEK293A cells, which were reconstituted with wild-type
LATS2 or LATS2 mutants (T168A or T436A). As expected, the
amount of TAZ decreased and phosphorylation at YAP Ser127
and TAZ Ser89 increased in LATS2-expressing cells (Fig. 5A).
In particular, such changes were more noticeable in the LATS2
T436A mutant-expressing cells. The TAZ level was by 52% lower
(Fig. 5 A and C) and phosphorylation levels at YAP Ser127 and
TAZ Ser89 were higher in LATS2 T436A mutant-expressing cells
than those in wild-type LATS2-expressing cells (Fig. 5 A–C).
However, such changes were less noticeable in the LATS2 T168A
mutant-expressing cells. LATS2 also phosphorylates YAP at
Ser109. Therefore, the amount of phosphorylation at YAP Ser109
between the wild-type and the LATS2 mutant-expressing cells was
additionally compared. Only LATS2 T436A mutant-expressing
cells had greater levels of phosphorylation at YAP Ser109 than
wild-type LATS2-expressing cells (SI Appendix, Fig. S4). These
results support the conclusion that O-GlcNAcylation at LATS2
Thr436 inhibits its kinase activity.
Next, qRT-PCR was performed to measure the mRNA levels
of connective tissue growth factor (CTGF) and cysteine-rich
angiogenic inducer 61 (CYR61), which are YAP/TAZ tran-
scriptional targets. The mRNA levels of both molecules were
lower in LATS2 T436A mutant-expressing cells than those in
wild-type LATS2-expressing cells (Fig. 5D). Similarly, the ex-
pression levels of CTGF and CYR61 were lower in cells
expressing the T436A mutant compared to cells expressing the
wild type (Fig. 5E). These results revealed the same tendency
when intracellular O-GlcNAcylation in MDA-MB-231 cells was
reduced by OGT knockdown condition (SI Appendix, Fig. S5 A
and B). A strong positive correlation has been reported between
CTGF/CYR61 and LATS2 mRNA levels in various cancer cells
(41). LATS2 and NF2 are negative regulators and transcriptional
targets of YAP/TAZ (41, 42). LATS2 and NF2 mRNA levels were
reduced by OGT knockdown in MDA-MB-231 cells (SI Appendix,
Fig. S5C), similar to the reductions in CTGF and CYR61 mRNA
levels. In addition, NF2 transcription levels decreased significantly
by expressing wild-type LATS2, and this decrease was enhanced
more in LATS2 T436A mutant-expressing cells (Fig. 5F). These
findings indicate that inactivation of LATS2 by O-GlcNAcylation
at LATS2 Thr436 enhances YAP/TAZ activity. Taken together, it
was concluded that O-GlcNAcylation at LATS2 Thr436 sup-
pressed the Hippo pathway by inhibiting LATS2 activity.
LATS2 O-GlcNAcylation Promotes Tumor Growth by Enhancing Cell
Proliferation. LATS2 suppresses cell proliferation by inhibiting
transcription of YAP/TAZ target genes related to cell pro-
liferation, such as CTGF and CYR61 (7, 49, 50). Therefore, the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)







Fig. 5. O-GlcNAcylation at LATS2 Thr436 suppresses its kinase activity. (A–F) Wild-type (WT) LATS2 or LATS2 mutants were stably expressed in LATS1/2-dKO
HEK293A cells. (A) Cell lysates were immunoblotted with the relevant antibodies. (B) The phosphorylation levels at YAP Ser127 were normalized to the YAP
level, and the YAP expression level was normalized to the GAPDH level. (C) Phosphorylation levels at TAZ Ser89 were normalized to the TAZ level, and the
TAZ expression level was normalized to the GAPDH expression level. (D) CTGF and CYR61 mRNA levels were determined by qRT-PCR. All values were nor-
malized to the GAPDH mRNA level. (E) Lysates of the indicated Flag-LATS2 stably expressing LATS1/2-dKO HEK293A cells were immunoblotted with anti-
CYR61 and anti-CTGF antibodies. CTGF and CYR61 expression levels were normalized to β-actin expression level. (F) NF2 mRNA level was determined by qRT-
PCR. The NF2 mRNA level was normalized to GAPDH mRNA level. (B–F) Data are presented as mean ± SEM from at least three independent experiments.
Statistical significance was determined by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.005).








LATS2 Thr436 promotes cell proliferation. The optical density (OD)
540-nm values obtained for wild-type LATS2 and T436A mutant-
expressing LATS1/2-dKO HEK293 cells were 31% and 62% lower
than those of LATS2-nonexpressing cells, respectively, 4 d after
seeding (Fig. 6A). Additionally, the effect of LATS2O-GlcNAcylation
on tumor growth was investigated in vivo with male BALB/c nude
mice. The size and weight of tumors formed from T436A mutant-
expressing cells were 82% and 62% smaller than those of tumors
formed from wild-type LATS2-expressing cells, respectively (Fig. 6B).
These results indicate that O-GlcNAcylation at LATS2 Thr436 pro-
motes tumor growth by enhancing cell proliferation.
To confirm whether LATS2 O-GlcNAcylation affects tumor
size by inducing dysregulation of the Hippo pathway, tumor
tissues were obtained from both tumor-induced mouse models
and breast cancer patients. The tumor-induced mouse model was
generated by expressing the polyomavirus middle T oncogene in
C57BL/6NHsd mice. As commonly observed in various cancers,
OGT and O-GlcNAcylation levels in mouse mammary tumor
tissues were higher than that in normal mammary tissues, and
YAP and TAZ expression was more dominant in tumor tissues
(Fig. 6C). Additionally, the amount of LATS2 precipitated with
sWGA was higher in tumor tissues than that in normal tissues
(Fig. 6D). The same results were observed with a similar ex-
periment using human clinical samples (Fig. 6E). These findings
support our conclusion that LATS2 O-GlcNAcylation induces
excessive cell proliferation contributing to tumor growth.
Overall, the conclusions of this study can be summarized as
follows: LATS2 O-GlcNAcylation at Thr436 inhibits its phos-
phorylation, which is necessary for LATS2 activation, by blocking
the interaction with MOB1. This blockage increases the quantity
of activated YAP/TAZ. As a result, O-GlcNAcylation at LATS2
Thr436 enhances cell proliferation by inducing the transcription
of YAP/TAZ target genes, which positively regulate cell pro-
liferation. O-GlcNAcylation at LATS2 Thr436 increases NF2
and LATS2 transcription by inhibiting its activity. However, even
if the newly synthesized NF2 recruits more LATS2 to the MST-
MOB1 complex, activation of LATS2 might be impeded by
O-GlcNAcylation at LATS2 Thr436 which blocks MOB1-LATS2
interactions. Similarly, even if LATS2 transcription rates in-
crease, its effect on YAP/TAZ activity might be blocked by
O-GlcNAcylation at LATS2 Thr436 in the same manner (Fig. 7).
Thus, this study suggests that O-GlcNAcylation of LATS2 con-
tributes to dysregulation of the Hippo pathway by inhibiting
LATS2 activation.
Discussion
YAP and TAZ are highly expressed and more active in various
cancer cells (20, 44–46). It was hypothesized that abnormally



































































































































Fig. 6. LATS2 O-GlcNAcylation promotes tumor growth. (A) LATS1/2-dKO HEK293A cells, which were reconstituted with the wild-type (WT) LATS2 or T436A
mutant, were seeded on 24-well plates at 2 × 104 cells/well. MTT assays were performed after growth for the indicated time. (B) BALB/c nude mice (n = 7/
group) were injected with 1 × 107 of the indicated cells into the hypodermis. Tumor size and weight were measured 60 d after injection. (C and D) Mammary
tissue samples were obtained from tumor-induced (T) and normal (N) C57BL/6NHsd mice. Tissue samples were examined by Western blot using the indicated
antibodies (C). Tissue samples were precipitated by sWGA and then examined by Western blot analysis using an anti-LATS2 antibody (D). (E) Tumor tissue
samples (T) and adjacent noncancerous tissue samples (N) obtained from breast cancer patients were precipitated by sWGA and examined by Western blot
analysis using an anti-LATS2 antibody. (A, B, and E) Data are presented as mean ± SEM from at least three independent experiments. Statistical significance
was determined by one-way ANOVA (A) or the two-tailed Student’s t test (B and E) (*P < 0.05, **P < 0.01, ***P < 0.005).
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for dysregulation of the Hippo pathway. It has been recently
found that YAP O-GlcNAcylation enhances its activity by
blocking the interaction between YAP and LATS1 (32, 39). This
study reports that O-GlcNAcylation is deeply involved in the
Hippo pathway. Activated YAP/TAZ induces transcription of
LATS2 and NF2, thereby increasing activation of LATS2 which
inhibits YAP/TAZ activity (41). This process is a negative feed-
back loop in the Hippo pathway that helps maintain homeostasis
in terms of intracellular YAP/TAZ levels and activities. Thus, it
can be logically inferred that YAP O-GlcNAcylation decreases
TAZ levels by stimulating LATS2 activity. However, the amount
of TAZ remains high and LATS activity is inhibited in various
cancer cells (43, 44, 51). Therefore, it was hypothesized that other
components of the Hippo pathway are O-GlcNAcylated, leading
to a network-level perturbation in cancer cells.
Our study revealedO-GlcNAcmodifiedHippo pathway components,
MST1 and LATS2, and identified several LATS2 O-GlcNAcylation
sites. Of those sites, O-GlcNAcylation at Thr436 in LCD2 showed
the potential to hyperactivate YAP/TAZ and block an intrinsic
negative feedback loop in the Hippo pathway by inhibiting LATS2
activation. Additionally, considering that O-GlcNAcylation com-
petes with phosphorylation for the same YAP Ser109 residues (32),
LATS2 O-GlcNAcylation is expected to have a synergistic effect on
dysregulation of the Hippo pathway, asO-GlcNAcylation of LATS2
Thr436 increased the chance of O-GlcNAcylation at YAP Ser109
by inhibiting phosphorylation at YAP Ser109. Thus, findings about
O-GlcNAcylation of LATS2 would be key to understanding how the
Hippo pathway is dysregulated in cancer cells.
Hyperglycemia enhances breast tumor growth (52).O-GlcNAcylation
levels of wild-type LATS2 dramatically increased under 25-mM
glucose condition, whereas O-GlcNAcylation levels of the T436A
mutant were not affected by the glucose concentration in the
media (SI Appendix, Fig. S6). Thus, O-GlcNAcylation at LATS2
Thr436 may be involved in high-glucose-stimulated breast tumor
growth.
Thr168 and Thr340 were identified as major O-GlcNAcylation
sites in the linker region between LCD1 and LCD2 of LATS2.
However, O-GlcNAcylation at these residues did not have a def-
inite inhibitory effect on LATS2 activity. In particular, LATS2
T168A mutant kinase activity was not promoted (Fig. 5 A–C and
SI Appendix, Fig. S4), even though phosphorylation levels of the
hydrophobic motif and activation loop were significantly higher in
the LATS2 T168A mutant than in the wild-type LATS2 (Fig. 4 A
and C). LCD2 is essential for the function of LATS2 (53), whereas
the exact function of the linker region is unknown. The LATS2-
T168M mutation has been observed in a few cancer samples (54).
In addition, the Ser172 residue adjacent to Thr168 is one of the
sites that is phosphorylated by PKA (55). Phosphorylation by PKA
does not affect phosphorylation at the hydrophobic motif and
activation loop but enhances LATS2 activity (55). Therefore, we
speculate that the kinase activity of the LATS2 T168A mutant did
not increase, possibly due to the inhibition of phosphorylation at
Ser172 or a conformational change in the LATS2 T168A mutant.
Studies about O-GlcNAcylation of the Hippo pathway have
only focused on tumor growth. However, TAZ expression, which
is strongly influenced by O-GlcNAcylation at LATS2 T436, is
correlated with cancer invasiveness (44). This study also found
that the transcription and expression levels of hyaluronan-
mediated motility receptor (RHAMM), a target gene regulated
by YAP/TAZ, and the phosphorylation levels of ERK essential
for its activation decreased in response to OGT knockdown in
MDA-MB-231 cells (SI Appendix, Fig. S7). RHAMM enhances
cancer motility by activating ERK (56). These results suggest that
O-GlcNAcylation might affect cancer metastasis by regulating the
Fig. 7. Model for enhancing tumor growth due to the Hippo pathway being interrupted by LATS2 O-GlcNAcylation. The O-GlcNAcylation at LATS2 Thr436 by
OGT interrupts the interaction with MOB1. Therefore, phosphorylation of the hydrophobic motif (HM) and activation loop (AL) essential for LATS2 activity
decreases. Activated YAP and TAZ increase in response to LATS2 inactivation, which enhances transcription of CTGF, CYR61, NF2, and LATS2. However, even if
the transcription rates of NF2 and LATS2 increase, the negative feedback loop would not effectively work by LATS2 O-GlcNAcylation in cancer cells. Con-
sequently, O-GlcNAcylation at LATS2 Thr436 disrupts the Hippo pathway, possibly enhancing tumor growth.








Hippo pathway. In addition, carcinogenesis can be induced by
defects in the negative feedback loop of the Hippo pathway
arising from LATS2 knockout (57), and the increase of intra-
cellular O-GlcNAcylation level during malignant transformation is
necessary for carcinogenesis (58, 59). Thus, the present results sug-
gest that LATS2 O-GlcNAcylation might cause carcinogenesis by
blocking the negative feedback loop of the Hippo pathway. Fur-
thermore, the Hippo pathway is closely related to cellular develop-
ment by regulating stem cell self-renewal (60), so O-GlcNAcylation
would be expected to affect cellular development by regulating the
Hippo pathway. Hence, we hope that this study will lead to new
findings about various physiological functions of O-GlcNAcylation in
the Hippo pathway.
Materials and Methods
Cell Culture and Reagents. The nontumorigenic MCF10A breast epithelial cell line
was cultured in Dulbecco’s modified Eagle’s medium/Ham’s nutrient mixture F12
(DMEM/F12) (Thermo Fisher Scientific) supplementedwith 5%horse serum, 10 μg/
mL insulin, 20 ng/mL epidermal growth factor (EGF), 100 ng/mL cholera toxin,
500 ng/mL hydrocortisone, 100 U/mL penicillin, and 100 μg/mL streptomycin. The
breast cancer cell lines MCF7, MDA-MB-468, and MDA-MB-231 were cultured in
DMEM (Lonza) with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and
100 μg/mL streptomycin. The HEK293, HEK293FT, HEK293A, and LATS1/2-dKO
HEK293A cell lines were cultured in DMEM with 10% FBS, 100 U/mL penicillin,
and 100 μg/mL streptomycin. All cells used in this studywere grown at 37 °C in 5%
CO2. Thiamet-G was supplied by Injae Shin, Yonsei University, Seoul, Korea.
Transfection and Retrovirus Infection. Cells were small interfering RNA (siRNA)
transfected with Lipofectamine RNAi MAX (Invitrogen) according to the
manufacturer’s transfection protocol. The siRNA sequences used in this study
are described in SI Appendix, Materials and Methods. Transfection was per-
formed with polyethylenimine (Sigma-Aldrich) as described previously for
transient overexpression of the target proteins (61). The mammalian expres-
sion plasmids for Myc-LATS1 and Myc-LATS2 were generated by inserting
LATS1 or LATS2 cDNA into the pcDNA3.0 vector. The pcDNA3.0-Myc-LATS2
deletion mutants (Δ161-402 and Δ403-480) were kindly provided by Quan
Chen, Nankai University, Tianjin, China. Various LATS2 mutants for the iden-
tified O-GlcNAcylation sites were generated using site-directed mutagenesis
and the QuikChange site-directed mutagenesis kit (Agilent Technologies).
The wild-type and each O-GlcNAcylation-deficient LATS2 mutant DNAs
were cloned into the Flag-tagged pMSCV vector. Two packaging plasmids
(pCMV-VSV-G and pCMV-Gag-Pol) and retroviral constructs were cotrans-
fected in HEK293FT cells with Lipofectamine 2000 (Invitrogen) for 48 h
according to the manufacturer’s transfection protocol. MDA-MB-231 and
LATS1/2-dKO HEK293A cells were infected in the presence of polybrene (4
μg/mL) using retroviral supernatants and the virally infected cells were se-
lected with 1 to 2 μg/mL of puromycin (Sigma-Aldrich). The pMSCV-puro,
pCMV-VSV-G, and pCMV-Gag-Pol vectors were kindly provided by Dae-Sik
Lim, Korea Advanced Institute of Science and Technology, Daejeon, Korea.
Protein Extraction from Tissue Samples.A total of four pairs of frozen deidentified
human triple negative breast cancer and adjacent noncancerous tissues collected
in 2015 were obtained from Yonsei University Cancer Center, Seoul, Korea. This
study was approved by the Yonsei University Institutional Review Board (IRB No.
7001988–201910-BR-732-01). Mouse breast tumors were induced by expression
of the polyomavirus middle T oncogene in C57BL/6NHsd mice, as described
previously (62). Tissue samples from patients and mice were homogenized using
a Dounce tissue homogenizer in NET buffer (150 mM NaCl, 50 mM Tris, pH 7.4,
1 mM EDTA, and 1% Nonidet P-40) supplemented with phosphatase inhibitor
mixture (Roche) and protease inhibitor mixture (Roche). Homogenates were
centrifuged at 14,000 rpm for 20 min at 4 °C, and the supernatants were col-
lected to perform sWGA precipitation, and Western blotting.
Nuclear and Cytosol Fractionation. Cells were incubated in ice-cold hypotonic
buffer (5 mM Tris pH 7.5, 100 μM dithiothreitol (DTT), 50 μM ethyl-
enediaminetetraacetic acid (EDTA), and 0.5% Nonidet P-40) for 15 min and
centrifuged at 3,400 × g for 3 min at 4 °C. The supernatant was retained as
the cytosolic fraction, the pellet was washed with PBS and centrifuged again
at 3,400 × g for 3 min at 4 °C. To obtain the nuclear fraction, the pellet was
incubated in RIPA buffer (150 mM NaCl, 50 mM Tris·HCl, pH 7.4, 2 mM EDTA,
0.1% SDS, 0.5% deoxycholate, 1% Nonidet P-40, and 50 mM NaF) on ice for
10 to 15 min and centrifuged at 18,000 × g for 10 min at 4 °C. The super-
natant of the lysed pellet was collected as the nuclear fraction.
Immunoprecipitation, sWGA Precipitation, and Western Blotting. Cells were
lysed in RIPA buffer supplemented with phosphatase inhibitor mixture and
protease inhibitor mixture for immunoblotting. The cells for immunopre-
cipitation or sWGA precipitation were solubilized in lysis buffer (500 mM Tris,
pH 7.5, 250 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, and 10 mM DTT)
supplemented with phosphatase inhibitor mixture and protease inhibitor
mixture or NET buffer supplemented with phosphatase inhibitor mixture
and protease inhibitor mixture. Immunoprecipitation, sWGA precipitation,
and Western blotting were performed as described previously (63). The
antibodies used for Western blot and immunoprecipitation are described in
SI Appendix, Materials and Methods. The results acquired by Western blot-
ting were quantified using Multi Gauge ver. 3.1 software (Fuji Film Corp.).
Xenograft Mouse Experiment. LATS1/2-dKO HEK293A cells which were recon-
stituted with wild-type LATS2 or T436A mutant were harvested using trypsin/
EDTA solution and washed with PBS. Cells were suspended at 1 × 107 per 100 μL
of PBS and injected into 5-wk-oldmale BALB/c nudemice (n = 7/group) purchased
fromDBL. Themice were housed in the Yonsei laboratory animal research center.
Tumor size and weight of each group were measured 60 d after injection. Tumor
volume was calculated as 0.5 × L (length) ×W (width)2. This study was performed
in accordance with the guidelines of the Yonsei University Institutional Animal
Care Use Committee after review and approval (IACUC-A-202001-100102).
Immunofluoresence. MDA-MB-231 cells were grown on 0.17 ± 0.01 mm thickness
coverslips (Glaswarenfabik Karl Hecht GmbH and Co.). The cells were fixedwith 3%
formaldehyde (Fluka) for 5 min at 37 °C, then fixed again with 0.5% formaldehyde
for 30 min at room temperature. The cells were washed with PBS and incubated in
a quenching solution (50 mM NH4Cl in PBS) for 30 min at 4 °C. The cells were
washed in PBS for 10 min and permeabilized with 0.2% Triton X-100 (Biotech) or
0.3% saponine (Sigma) in PBS containing 0.1%bovine serum albumin (BSA).Mouse
anti-YAP1 antibody (1:50) or rabbit anti-TAZ antibody (1:50) was applied for 2 h to
detect endogenous YAP or TAZ, followed by rinsing with PBS containing 0.1% BSA
two times for 5 min. The cells were incubated with Alexa Fluor 488-conjugated
secondary antibodies (1:500) (Invitrogen) for 1 h. After rinsing twice with PBS
containing 0.1% BSA, the cells were mounted on a glass slide with Mowiol con-
taining 4′, 6-diamidino-2-phenylindole. Images were collected on a Zeiss LSM 700
confocal microscope (Carl Zeiss) and analyzed with Zeiss ZEN software.
Cell Proliferation Assay. LATS1/2-dKO HEK293A cells, which were recon-
stituted with wild-type LATS2 or T436A mutant, were seeded into 24-well
plates at 2 × 104 cells per well. After 1, 2, 3, and 4 d, 600 μL of MTT solution
(0.5 mg/mL MTT) was added to each well and the cells were incubated at
37 °C for 40 min. The MTT solution was removed, and 600 μL of DMSO was
added to each well. Absorbance was measured at 540 nm using an Epoch
microplate spectrophotometer (BioTek).
Quantitative RT-PCR Analysis. Total RNA was extracted from cells using TRIzol
reagent (Invitrogen). To synthesize cDNA, reverse transcription was carried
out using ReverTra Ace qPCR RT Master Mix (Toyobo Co.) according to the
manufacturer’s instructions. Real-time PCR was performed with oligonucle-
otide primers using SYBR Premix Ex Taq (Takara) on an Applied Biosystems
7300 Sequence Detection System (Applied Biosystems). The following PCR
program was used; initial denaturation at 95 °C for 2 min; the cDNA was
amplified for 40 cycles with the following settings: denaturation at 95 °C for
5 s, annealing at 60 °C for 31 s, and elongation at 72 °C for 31 s. The DNA was
dissociated at 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s, and 60 °C for
1 min. The mRNA levels of CTGF, CYR61, RHAMM, and NF2 were normalized
to those of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR
primer sequences are described in SI Appendix, Materials and Methods.
Mapping of the LATS2 O-GlcNAcylation Sites Using Mass Spectrometry. The eluted
LATS2 sample was subjected to electrophoresis in a 4 to 12% Bis-Tris NuPAGE gel
(NOVEX) and stained with Coomassie Brilliant Blue (Sigma). The band corre-
sponding to LATS2 was excised from the gel and subjected to in-gel tryptic di-
gestion according to a standard protocol (64). Trypsin/Lys-CMix, mass spectometry
grade (Promega) was used in this procedure. Mass spectra of extracted
peptide samples were obtained using an Orbitrap Fusion Tribrid mass
spectrometer (Thermo Fisher Scientific) interfaced with a nanoAcquity
UPLC (Waters) as described previously in published methods (65). The raw
data were compared with a Uniprot human database (entry no. 173,324) using
the SEQUEST HT search engine in Proteome Discoverer 2.2 (Thermo Fisher Sci-
entific). Trypsin was selected as the proteolytic enzyme with a maximum allow-
ance of up to two missed cleavages. The carbamidomethyl of cysteine was
considered a fixed modification, and variable modification was set for oxidation
of methionine and O-GlcNAcylation of serine and threonine with a maximum of
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three posttranslational modifications at one peptide. Weight of the b, y ions was
set to 0.5 and weight of the c, z ions was set to 1, relatively. Peptides were
identified with ≥95% confidence and filtered at a 1% false-discovery rate.
Statistical Analysis. Data are expressed as mean ± SEM based on at least three
independent experiments. The statistical analysis was performed with the
two-tailed Student’s t test for two groups and by one-way analysis of vari-
ance for multiple groups. A P value <0.05 was considered significant.
Data Availability. The authors confirm that all data supporting the findings of
this study are available within the article and its supplementary information.
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